Milan

• Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1 Recruiting
  2023-509428-16-00 10 2024-10-15 HIV-1 Infection
• An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to ch … Recruiting
  2024-516782-36-00 4 2024-10-15 metastatic or recurrent endometrial or ovarian carcinosarcoma
• IDE196 (Darovasertib) in Combination with Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Recruiting
  2023-506686-66-01 10 2024-10-09 HLA-A2 negative metastatic uveal melanoma
• An extension study to find out if multiple treatment cycles of rozanolixizumab are safe and work in children with myasthenia gravis Recruiting
  2022-502075-34-00 5 2024-10-08 Generalized Myasthenia Gravis
• 202301CPC Redefine-HF Recruiting
  2023-508581-15-00 5 2024-10-08 Heart condition
• Comparison between ABP 234 and Keytruda® (Pembrolizumab) Recruiting
  2024-514304-14-00 1 2024-10-08 Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
• Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting
  2023-508012-35-00 5 2024-10-02 Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB
• A study to test the efficacy and safety of riliprubart against the usual treatment of intravenous immunoglobulin (IVIg) in people with chron … Recruiting
  2023-508338-33-00 5 2024-10-01 Chronic Inflammatory Demyelinating Polyneuropathy
• A Study to Evaluate ARV-393 in Adult Participants with Advanced Non-Hodgkin’s Lymphoma Recruiting
  2023-510136-36-00 1 2024-09-27 Advanced Non-Hodgkin’s Lymphoma
• A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients w … Recruiting
  2023-507064-39-00 5 2024-09-26 generalized Myasthenia Gravis
• A Phase 2/3 study to evaluate safety and efficacy of the combination of Bel- CHOP/ Fol-COP drugs against CHOP in newly diagnosed Peripheral … Recruiting
  2023-507803-76-00 10 2024-09-26 Peripheral T-Cell Lymphoma
• A Placebo-Controlled Study of Inhaled Pirfenidone in Progressive Pulmonary Fibrosis Recruiting
  2023-508429-29-00 4 2024-09-26 Progressive Pulmonary Fibrosis
• Substudy 06D: Combination Therapies in 2L Advanced Gastroesophageal Adenocarcinoma Recruiting
  2023-509306-29-00 9 2024-09-26 Gastroesophageal cancer
• Substudy 06C: Combination Therapies in Gastroesophageal Adenocarcinoma Recruiting
  2023-509307-33-00 9 2024-09-26 Gastroesophageal cancer
• A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Recruiting
  2023-508811-21-00 10 2024-09-25 Refractory Focal Onset Epilepsy
• Regorafenib for recurrent meningioma. A multicenter, randomized phase II study (MIRAGE trial) Recruiting
  2024-510954-28-01 4 2024-09-23 grade 1, 2 and 3 meningioma
• A study to characterise the safety, tolerability and efficacy of LY4170156 in subjects with advanced solid tumors Recruiting
  2024-511238-11-00 1 2024-09-20 Ovarian cancer, endometrial cancer, cervical cancer, non-small cell lu
• Clinical trial testing an investigational drug RVU120 for myelofibrosis (myeloproliferative neoplasm, MPN) Recruiting
  2024-511688-27-00 4 2024-09-19 Myelofibrosis
• A study of niraparib in combination with abemaciclib for late line treatment of ovarian cancer: a single center, open label, single arm, pha … Recruiting
  2022-501910-79-01 7 2024-09-18 Ovarian cancer
• A follow-up study to test long-term treatment with BI 1015550 in people with pulmonary fibrosis who took part in a previous study with BI 10 … Recruiting
  2023-507353-15-00 5 2024-09-10 idiopathic pulmonary fibrosis (IPF)
• HARMONi-3 Recruiting
  2024-513087-26-00 5 2024-09-10 Metastatic Non-small Cell Lung Cancer
• Study evaluating whether giving 177Lu-PSMA-617 to men having a spreading prostate cancer which does not respond well to the current standard … Recruiting
  2022-502408-57-00 5 2024-09-04 Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients hav
• Comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS Recruiting
  2023-505051-43-00 5 2024-09-04 juvenile idiopathic arthritis
• Trastuzumab Deruxtecan (T-DXd) for Subjects with Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC0 Breast Cancer … Recruiting
  2023-505616-38-00 4 2024-09-04 Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (

Showing 889–912 of 2,361 trials